Frontlight ResearchEarly access
CompletedPhase 4
A Randomized Trial of GVS Alone vs. Propranolol
Key facts
- Who runs it
- Taipei Veterans General Hospital, Taiwan
- Where
- Taiwan2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 120 people enrolled
- Started
- Apr 2010
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- propranolol
- Record updated
- 18 August 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (4)Hide the full registry criteria
Who can take part
- patients with live cirrhosis and/or hepatoma
- Aged 18 to 80, who had endoscopy-Proven EV(-)GV(+)or EV<GV
Who cannot take part
- Patients had previous endoscopic, surgical treatment or Transjugular Intrahepatic Portosystemic Shunt
- Had a terminal illness of any major organ system,such as heart failure, kindey failure,COPD
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Design a randomized trial to compare the effect of endoscopic cyanoacrylate injection obliteration versus non-selective beta-blocker in the primary prevention of gastric variceal bleeding.
The 2 groups in the trial
- CyanoacrylateNo study treatment, for comparison
Endoscopic Cyanoacrylate Injection treatment of primary prevention GVB
- PropranololExisting treatment, for comparison
Propranolol is used for primary prevention of GVB
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker
- Record updated
- 18 August 2026